Baker Avenue Asset Management LP Takes $707,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baker Avenue Asset Management LP bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 673 shares of the biopharmaceutical company's stock, valued at approximately $707,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Sigma Planning Corp boosted its stake in shares of Regeneron Pharmaceuticals by 4.1% during the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company's stock worth $430,000 after acquiring an additional 16 shares during the period. Assetmark Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 8.7% during the 3rd quarter. Assetmark Inc. now owns 103,980 shares of the biopharmaceutical company's stock worth $109,308,000 after acquiring an additional 8,289 shares during the period. Windward Capital Management Co. CA acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $420,000. CWA Asset Management Group LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $298,000. Finally, Stiles Financial Services Inc lifted its holdings in Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Stiles Financial Services Inc now owns 3,432 shares of the biopharmaceutical company's stock worth $3,606,000 after purchasing an additional 89 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on REGN. Oppenheimer dropped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $1,107.25.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $4.68 during midday trading on Tuesday, reaching $821.00. 677,553 shares of the stock were exchanged, compared to its average volume of 523,791. The stock has a market capitalization of $90.22 billion, a PE ratio of 20.43, a P/E/G ratio of 3.13 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $784.96 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a fifty day moving average price of $1,014.52 and a 200 day moving average price of $1,037.74.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.